Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2022

Same author

Modeled Daily Ingested, Absorbed and Bound Phosphorus: New Measures of Mineral Balance in Hemodialysis Patients.

American journal of nephrology·2019

Same author

The Phosphate Content of Prescription Medication: A New Consideration.

Therapeutic innovation & regulatory science·2018

Same author

Inherent Errors in the Quantitation of Dialysis Delivery: Implications For CAPD and Daily Hemodialysis.

Home hemodialysis international. International Symposium on Daily Home Hemodialysis·2017

Same author

Going Upstream: Coordination to Improve CKD Care.

Seminars in dialysis·2016

Same author

Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial.

Journal of the American Society of Nephrology : JASN·2015

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Sevelamer carbonate.

Mary M Barna¹, Toros Kapoian, Neeta Bahal O'Mara

¹Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.

The Annals of Pharmacotherapy

|December 4, 2009

Summary

This summary is machine-generated.

Sevelamer carbonate effectively manages hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. It lowers phosphorus levels with fewer gastrointestinal issues than sevelamer hydrochloride, which is no longer available.

More Related Videos

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

Related Experiment Videos

Last Updated: Jun 18, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

Area of Science:

Nephrology
Pharmacology

Background:

Hyperphosphatemia is a common complication in patients with chronic kidney disease (CKD).
Phosphate binders are essential for managing elevated serum phosphorus levels in CKD patients.

Purpose of the Study:

To review the pharmacology, pharmacokinetics, clinical efficacy, safety, and therapeutic role of sevelamer carbonate.
To evaluate sevelamer carbonate for treating hyperphosphatemia in chronic kidney disease (CKD) patients.

Main Methods:

Literature search of MEDLINE and other databases (1966-August 2009) using keywords: CKD, hyperphosphatemia, sevelamer carbonate.
Inclusion of all published English-language articles, reviews, abstracts, and presentations on sevelamer carbonate in humans.

Main Results:

Sevelamer carbonate is approved for controlling serum phosphorus in dialysis patients with CKD.
It effectively lowers phosphorus and calcium-x-phosphorus product, comparable to sevelamer hydrochloride.
Sevelamer carbonate showed fewer gastrointestinal adverse events and less metabolic acidosis than sevelamer hydrochloride.

Conclusions:

Sevelamer carbonate is a viable treatment for hyperphosphatemia in dialysis patients with CKD.
It lowers serum phosphorus with minimal impact on calcium or chloride levels.
Its comparative efficacy against other phosphate binders requires further establishment.